Drug intelligence / Profile preview

CIB-201

Development stage: Preclinical
Lead developer: Cellinfinity Bio
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CIB-201 is an experimental autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by Cellinfinity Bio for the treatment of solid tumors. The therapy is engineered using the company's proprietary platform to target a novel, undisclosed molecular target. Cellinfinity Bio focuses on identifying target innovations and enhancements to improve the efficacy and persistence of CAR-T cells within the immunosuppressive environment of solid tumors. As of early 2026, CIB-201 is in the discovery and lead optimization stage of development.

Beyond the preview

Go deeper on CIB-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIB-201.

Explore the full profile